Stay updated on Pembrolizumab for Rare Tumors Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Rare Tumors Clinical Trial page.

Latest updates to the Pembrolizumab for Rare Tumors Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2 on the page.SummaryDifference0.0%

- Check20 days agoChange DetectedNew study record dates were added (2026-01-12, 2026-01-29, 2026-01, 2028-12-31). Old dates (2025-07-31, 2025-12-31, 2025-07-29, 2025-07) were removed and the revision tag updated from v3.4.0 to v3.4.1.SummaryDifference0.3%

- Check27 days agoChange DetectedGlossary toggle added and a new 'Revision: v3.4.0' label appears alongside 'Last Update Submitted that Met QC Criteria'. The previous items 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4' have been removed.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4 on the page. This appears to be a minor metadata update with no visible content changes.SummaryDifference0.0%

- Check63 days agoChange DetectedAdded a Texas location under Locations and updated the revision to v3.3.3. Removed the HHS Vulnerability Disclosure and the Texas Locations entry from the prior revision (v3.3.2).SummaryDifference0.2%

- Check92 days agoChange DetectedAdded note that publications are automatically filled from PubMed and included Revision: v3.3.2. Removed the older text stating PubMed publications are automatically created by ClinicalTrials.gov and may not be about the study.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab for Rare Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Rare Tumors Clinical Trial page.